 |
- Conditions: Dry Eye; Dry Eye Syndrome; Blepharitis; Meibomian Gland Dysfunction; Eye Pain; Punctate Epithelial Keratitis; Punctate Keratitis; Tear Film Insufficiency; Kerato Conjunctivitis Sicca; Eye Diseases
Intervention: Device: Artificial tears (classified by MHRA as a medical device)
Sponsors: Guy's and St Thomas' NHS Foundation Trust; Fight for Sight
Recruiting - Condition: Myopia
Interventions: Drug: Atropine Sulfate; Other: Placebo
Sponsor: Belfast Health and Social Care Trust
Not yet recruiting - Safety and Efficacy of a Sub-epitheilal Transform™ Corneal Allograft (TCA) for Presbyopia CorrectionConditions: Presbyopia; Refractive Errors
Intervention: Other: Sub-epitheilal TCA Inlay
Sponsor: Allotex, Inc.
Not yet recruiting - Condition: Optokinetic Nystagmus
Intervention: Device: CAVA
Sponsors: Emily Woodhouse; University of East Anglia; Medical Research Council
Recruiting - Condition: Ocular Surface Disease
Intervention: Other: Autologous blood applied to dry eye
Sponsors: NHS Lanarkshire; Chief Scientist Office of the Scottish Government; NHS Research Scotland
Recruiting - Condition: Diabetic Macular Edema
Interventions: Procedure: Diode 577 nm subthreshold micropulse laser; Procedure: Standard threshold laser (532 nm laser)
Sponsors: Belfast Health and Social Care Trust; Northern Ireland Clinical Trials Unit
Recruiting - Condition: Hyperopia
Intervention: Other: Intrastromal TCA Inlay
Sponsor: Allotex, Inc.
Not yet recruiting - Condition: Presbyopia
Intervention: Other: TCA Intrastromal Inlay
Sponsor: Allotex, Inc.
Not yet recruiting - Condition: Corneal Astigmatism
Interventions: Device: Toric intraocular MX60T lens; Other: Standard MX60 plus corneal incisions
Sponsors: Ashford and St. Peter's Hospitals NHS Trust; Bausch & Lomb Incorporated
Recruiting - Conditions: Keratoconus; Fuchs Dystrophy; Corneal Disease
Interventions: Procedure: Femtosecond Laser; Procedure: Trephine blade
Sponsor: University of Southampton
Not yet recruiting - Conditions: Retinal Disease; Retinal Degeneration; Retinal Dystrophies
Intervention: Device: Long-wavelength autofluorescence imaging
Sponsor: Oxford University Hospitals NHS Trust
Not yet recruiting - Conditions: Optic Neuritis; Optic; Neuritis, With Demyelination
Intervention: Drug: Comparison of BN201 treatment with Placebo
Sponsors: Bionure Farma SL; Simbec Research
Recruiting - Conditions: Eye Diseases; Eye Infections; Eye Inflammation
Intervention: Device: Binocular OCT
Sponsors: University College, London; National Institute for Health Research, United Kingdom
Recruiting - Condition: Non-infectious Uveitis
Intervention: Drug: PP-001
Sponsor: Panoptes Pharma GmbH
Recruiting - A Study to Evaluate the Efficacy and Safety of RO6867461 in Participants With Diabetic Macular EdemaCondition: Diabetic Macular Edema
Interventions: Drug: Aflibercept; Drug: RO6867461; Drug: Sham Procedure
Sponsor: Hoffmann-La Roche
Recruiting - Condition: Retinal Detachment
Intervention:
Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Recruiting - Condition: Vision, Low
Interventions: Device: MED; Other: Buddy
Sponsors: University of Manchester; City, University of London; Schepens Eye Research Institute
Recruiting - Condition: Keratoconus
Intervention: Procedure: Customised CXL
Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Not yet recruiting - Condition: Behcet's Disease
Intervention: Drug: GSK1070806
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Not yet recruiting - Condition: Choroideremia
Intervention: Genetic: AAV2-REP1
Sponsor: Nightstar Therapeutics
Recruiting - Conditions: Diabetes Mellitus; Diabetic Retinopathy; Macular Edema
Interventions: Drug: Ranibizumab 0.5mg; Drug: THR-317 8mg; Drug: Sham injection
Sponsor: ThromboGenics
Recruiting - Conditions: Proliferative Diabetic Retinopathy; Diabetic Macular Edema
Intervention:
Sponsors: Belfast Health and Social Care Trust; National Institute for Health Research, United Kingdom
Recruiting - Conditions: Mitochondrial Diseases; Mitochondrial Myopathies; Progressive External Ophthalmoplegia; Progressive Ophthalmoplegia; Progressive; Ophthalmoplegia, External; Mitochondria DNA Deletion; MELAS; Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes; Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Intervention: Dietary Supplement: Nicotinamide Riboside
Sponsors: Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; MRC Mitochondrial Biology Unit
Recruiting - Condition: Hypermetropia
Intervention: Procedure: ReLEx SMILE
Sponsor: Carl Zeiss Meditec AG
Recruiting - Condition: Diabetic Retinopathy
Interventions: Drug: Fenofibrate 145 mg; Drug: Placebo Oral Tablet
Sponsors: University of Oxford; National Institute for Health Research, United Kingdom; University of Glasgow; University of Aberdeen; University of Dundee; University of Edinburgh; NHS Scotland Diabetic Retinopathy Screening Collaborative
Recruiting - Condition: Leber Hereditary Optic Neuropathy (Optic, Atrophy, Hereditary, Leber)
Interventions: Genetic: GS010; Other: Sham Intravitreal Injection
Sponsor: GenSight Biologics
Recruiting - Conditions: Cataract Extraction; Phacoemulsification; Glistenings; Intraocular Lens Implant; Hydrophobic Acrylic; Cataract Surgery; Light Scatter; Patient Satisfaction; Patient Related Outcome Measures
Intervention: Device: Cataract surgery
Sponsors: Guy's and St Thomas' NHS Foundation Trust; City, University of London; King's College London
Recruiting - Condition: Glaucoma, Angle-Closure
Intervention: Device: XEN45
Sponsor: Allergan
Recruiting - Condition: Stargardt Disease 1
Interventions: Drug: Zimura; Other: Sham
Sponsor: Ophthotech Corporation
Recruiting - Condition: Age Related Macular Degeneration (AMD)
Intervention: Other: No intervention
Sponsors: Frank G. Holz; Bayer; Moorfields Eye Hospital NHS Foundation Trust; Novartis Pharmaceuticals; Association for Innovation and Biomedical Research on Light and Image; City, University of London; European Clinical Research Infrastructure Network; La Fondation Voir et Entendre; Hoffmann-La Roche; Radboud University; University of Sheffield; University College, London; Carl Zeiss Meditec AG; Innovative Medicines Initiative
Recruiting - Condition: Choroideremia
Intervention:
Sponsor: Nightstar Therapeutics
Recruiting - Condition: Neovascular Age-related Macular Degeneration
Interventions: Biological: OPT-302; Biological: ranibizumab; Other: sham intravitreal injection
Sponsor: Opthea Limited
Recruiting - Conditions: Neurofibromatosis Type 1; Plexiform Neurofibroma; Optic Nerve Glioma
Intervention: Drug: Selumetinib
Sponsors: Great Ormond Street Hospital for Children NHS Foundation Trust; AstraZeneca
Not yet recruiting - Condition: Open Angle Glaucoma and Cataract
Intervention: Drug: Prostaglandins
Sponsor: Emily Woodhouse
Recruiting - Condition: Achromatopsia
Intervention: Biological: AAV - CNGB3
Sponsors: MeiraGTx UK II Ltd; Syne Qua Non Limited; EMAS Pharma
Recruiting - Conditions: Open Angle Glaucoma; Ocular Hypertension
Interventions: Drug: Netarsudil/Latanoprost 0.02%/0.005%; Drug: GANFORT®
Sponsor: Aerie Pharmaceuticals
Recruiting - Condition: Diabetic Retinopathy
Interventions: Drug: BI 1467335; Drug: Placebo
Sponsor: Boehringer Ingelheim
Recruiting - Condition: X-Linked Retinitis Pigmentosa
Intervention: Genetic: AAV-RPGR
Sponsors: MeiraGTx UK II Ltd; Syne Qua Non Limited; EMAS Pharma
Recruiting - Condition: Acanthamoeba Keratitis
Interventions: Drug: PHMB 0.08%; Drug: Propamidine 0.1%; Drug: placebo; Drug: PHMB 0.02%
Sponsor: SIFI SpA
Recruiting - Condition: Noninfectious Uveitis
Interventions: Drug: Filgotinib; Drug: Placebo to match filgotinib; Drug: Prednisone
Sponsor: Gilead Sciences
Recruiting - Condition: Age-Related Macular Degeneration
Interventions: Drug: SB11 (Proposed ranibizumab biosimilar); Drug: Lucentis (ranibizumab)
Sponsor: Samsung Bioepis Co., Ltd.
Recruiting - Conditions: Usher Syndrome, Type 2A; Retinitis Pigmentosa 39
Intervention:
Sponsors: Jaeb Center for Health Research; Foundation Fighting Blindness; Duke University; Oregon Health and Science University
Recruiting - Condition: Sjogren's Syndrome
Interventions: Drug: Filgotinib; Drug: GS-9876; Drug: Tirabrutinib; Drug: Filgotinib placebo; Drug: GS-9876 placebo; Drug: Tirabrutinib placebo
Sponsors: Gilead Sciences; Galapagos NV
Recruiting - Conditions: Epiretinal Membrane; Retinal Hemorrhage
Intervention: Device: Robot assisted surgery
Sponsor: University of Oxford
Recruiting - Condition: Uveal Melanoma
Interventions: Biological: IMCgp100; Drug: Dacarbazine; Biological: Ipilimumab; Biological: Pembrolizumab
Sponsor: Immunocore Ltd
Recruiting - Condition: Achromatopsia
Intervention: Biological: AAV - CNGB3
Sponsors: MeiraGTx UK II Ltd; EMAS Pharma; Syne Qua Non Limited
Recruiting - Conditions: Pro-opiomelanocortin (POMC) Deficiency Obesity (Heterozygous or Epigenetic); Leptin Receptor Deficiency Obesity; Bardet-Biedl Syndrome; Alstrom Syndrome
Intervention: Drug: Setmelanotide
Sponsor: Rhythm Pharmaceuticals, Inc.
Recruiting - Conditions: Leber Congenital Amaurosis (LCA); Eye Diseases; Eye Diseases, Hereditary; Retinal Diseases
Intervention: Biological: AAV OPTIRPE65
Sponsors: MeiraGTx UK II Ltd; Syne Qua Non Limited
Recruiting - Condition: Adenoviral Conjunctivitis
Interventions: Drug: SHP640; Drug: PVP-I 0.6%; Drug: Placebo
Sponsor: Shire
Recruiting - Condition: Primary Sjogren's Syndrome
Interventions: Biological: VAY736; Other: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - Condition: Graves' Disease
Intervention: Drug: K1-70 intramuscular
Sponsor: AV7 Limited
Recruiting - Conditions: Primary Open Angle Glaucoma; Normal Tension Glaucoma; Ocular Hypertension
Intervention:
Sponsor: University of Plymouth
Recruiting - Condition: Eye Injury Trauma
Intervention: Drug: Triamcinolone Acetonide
Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Recruiting - Conditions: Vitreous Diseases; Retinal Diseases; Choroidal Diseases
Intervention: Device: Swept-source optical coherence tomography (SS-OCT)
Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Recruiting - Condition: Leber Congenital Amaurosis
Intervention: Biological: AAV RPE65
Sponsor: MeiraGTx UK II Ltd
Recruiting - Condition: Leber's Hereditary Optic Neuropathy (LHON)
Intervention: Drug: Idebenone
Sponsor: Santhera Pharmaceuticals
Recruiting - Conditions: Vision Disorders; Reading Disabilities
Interventions: Device: Precision tinted lenses; Device: Non-beneficial tinted lenses
Sponsor: City, University of London
Recruiting - Condition: Melanoma, Ocular
Intervention: Combination Product: Melphalan/HDS
Sponsors: Delcath Systems Inc.; Novella Clinical
Recruiting - Condition: Mucopolysaccharidoses
Intervention:
Sponsors: Manchester Royal Eye Hospital; BioMarin Pharmaceutical
Recruiting - Condition: Retinopathy of Prematurity
Intervention: Drug: Ranibizumab
Sponsor: Novartis Pharmaceuticals
Recruiting - Conditions: Uveitis; Macular Edema
Interventions: Drug: Dexamethasone intravitreal implant 0.7 mg; Drug: Intravitreal Methotrexate 400 µg; Drug: Intravitreal Ranibizumab 0.5 mg
Sponsors: JHSPH Center for Clinical Trials; National Eye Institute (NEI)
Recruiting - Condition: Age- Related Macular Degeneration
Intervention: Drug: Minocycline
Sponsor: National Eye Institute (NEI)
Recruiting - Conditions: Myopia; Refractive Errors
Interventions: Procedure: Small incision lenticule extraction; Drug: Tobramycin and dexamethasone; Drug: Ofloxacin; Drug: Proxymetacaine 0.5%; Drug: Oxybuprocaine 0.4%
Sponsor: London Vision Clinic
Recruiting - Condition: Uveal Melanoma
Intervention: Drug: IMCgp100
Sponsor: Immunocore Ltd
Recruiting - Condition: Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Sponsors: Bayer; Regeneron Pharmaceuticals
Recruiting - Conditions: Glaucoma, Open-Angle; Ocular Hypertension
Interventions: Drug: Bimatoprost SR; Other: Sham Bimatoprost SR; Procedure: Selective Laser Trabeculoplasty; Other: Sham Selective Laser Trabeculoplasty
Sponsor: Allergan
Recruiting - Condition: Choroideremia
Intervention: Genetic: AAV-mediated REP1 gene replacement
Sponsors: University of Oxford; Moorfields Eye Hospital NHS Foundation Trust; University College, London
Recruiting - Condition: Primary Sjögren's Syndrome
Interventions: Drug: CFZ533 active - Cohort 1; Drug: CFZ533 placebo- Cohort 1; Drug: CFZ533 active - Cohort 2; Drug: CFZ533 placebo - Cohort 2; Drug: CFZ533 active -Cohort 3; Drug: CFZ533 active - Cohort 3
Sponsor: Novartis Pharmaceuticals
Recruiting - Condition: Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions: Radiation: Stereotactic radiotherapy (16 Gray or Sham); Drug: 0.5 mg ranibizumab
Sponsors: King's College Hospital NHS Trust; King's College London
Recruiting - Conditions: Health; Hypertension; Chronic Kidney Disease
Intervention:
Sponsor: University of Edinburgh
Recruiting - Conditions: Neuromyelitis Optica (NMO); NMO Spectrum Disorder (NMOSD)
Interventions: Drug: satralizumab (SA237); Drug: Placebo
Sponsor: Chugai Pharmaceutical
Recruiting - Conditions: Opsoclonus Myoclonus Syndrome; Neuroblastoma
Interventions: Drug: Dexamethasone acetate; Drug: dexamethasone and cyclophosphamide; Drug: dexamethasone and rituximab
Sponsor: Institut Curie
Recruiting - Conditions: Exudative Macular Degeneration; Retinal Hemorrhage
Interventions: Drug: Ranibizumab; Drug: C3F8 Gas; Drug: tPA
Sponsor: King's College Hospital NHS Trust
Recruiting - Condition: Retinal Vein Occlusion
Intervention: Drug: Minocycline
Sponsor: National Eye Institute (NEI)
Recruiting - Condition: Retinal Vein Occlusion
Intervention: Drug: Minocycline
Sponsor: National Eye Institute (NEI)
Recruiting - Conditions: Adenovirus; Anesthesia; Anxiety; Anxiolysis; Autism; Autistic Disorder; Bacterial Meningitis; Bacterial Septicemia; Benzodiazepine; Bipolar Disorder; Bone and Joint Infections; Central Nervous System Infections; Convulsions; Cytomegalovirus Retinitis; Early-onset Schizophrenia Spectrum Disorders; Epilepsy; General Anesthesia; Gynecologic Infections; Herpes Simplex Virus; Infantile Hemangioma; Infection; Inflammation; Inflammatory Conditions; Intra-abdominal Infections; Lower Respiratory Tract Infections; Migraines; Pain; Pneumonia; Schizophrenia; Sedation; Seizures; Skeletal Muscle Spasms; Skin and Skin-structure Infections; Thromboprophylaxis; Thrombosis; Treatment-resistant Schizophrenia; Urinary Tract Infections; Withdrawal; Sepsis; Gram-negative Infection; Bradycardia; Cardiac Arrest; Cardiac Arrhythmia; Staphylococcal Infections; Nosocomial Pneumonia; Neuromuscular Blockade; Methicillin Resistant Staphylococcus Aureus; Endocarditis; Neutropenia; Headache
Intervention: Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Sponsors: Daniel Benjamin; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); The EMMES Corporation
Recruiting
Clinical Trial Locations